44 results
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
Opportunistic Disease ... complex (MAC) disease ... A and B virus infection ... #OIs #HIVAIDS # ... IDSA #management
COVID-19 Infection - Clinical Presentation and Disease Progression for Severe Cases

Via https://doi.org/10.1007/s00134-020-05967-x

#COVID19 #Hospitalization #Disease #Progression #Severe
COVID-19 Infection ... Presentation and Disease ... 020-05967-x #COVID19 ... Hospitalization #Disease ... Coronavirus #Diagnosis #Management
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
Opportunistic Disease ... complex (MAC) disease ... A and B virus infection ... #OIs #HIVAIDS # ... IDSA #management
COVID-19: ICU Guidelines for the Non-Intensivist
Infection Control
Risk Factors for Severe Disease
Initial Laboratory Workup
COVID-19 Specific Medications
Respiratory
Cardiac
Hematologic
Neuro/Sedation

#COVID19 #ICU
COVID-19: ICU Guidelines ... Non-Intensivist Infection ... Factors for Severe Disease ... Laboratory Workup COVID ... NonIntensivist #diagnosis #management
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
Penicillium marneffei Infections ... Treating Acute Infection ... Prevention #Treatment #management ... opportunistic #infections ... #HIVAIDS #pharmacology
IDSA Recommendations for Treating Isospora belli Infection in HIV-AIDS
Treating Isospora belli Infection
General Management Considerations:
 • Fluid
Infection in HIV-AIDS ... Infection General ... Management Considerations ... Prevention #Treatment #management ... #HIVAIDS #pharmacology
Drugs Used for the Treatment of COVID-19 Infection

** Editor Note (from ophthalmology MD input) - Hydroxychloroquine/chloroquine
the Treatment of COVID ... -19 Infection ... Even with macular disease ... Medications #Treatment #COVID19 ... Pharmacology #Table #Management
Anti-IL6 Agents (Tocilizumab, Siltuximab) in COVID19

IL-6 activates T cells and macrophages, among other cell types (see
Siltuximab) in COVID19 ... -6 activates T cells ... correlate with severe COVID ... respiratory tract infection ... #Pharmacology #Management
IDSA Algorithm for the Management of Purulent skin and soft tissue infections (SSTIs). 
Mild infection: for
Algorithm for the Management ... Mild infection: ... 12 000 or <400 cells ... erysipelas with no focus ... SSTIs #Algorithm #Management
Hemophagocytic Lymphohistiocytosis (HLH)
Pathophysiology: Triggering factor (infection,...)→Activation of CD8 T cells (IFN-y) → Excessive activation of macrophages
Activation of CD8 T cells ... Phagocytosis of blood cells ... • Autoimmune diseases ... Adult-onset Still disease ... Lymphohistiocytosis #diagnosis #management